Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant

Yu Kyoung Oh, Taejong Sohn, Jeong Sook Park, Min Jeong Kang, Han Gon Choi, Jung Ae Kim, Won-Ki Kim, Jung Jae Ko, Chong Kook Kim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Here, we report the enhanced mucosal and systemic immunogenicity of human papillomavirus type (HPV) 16 L1 virus-like particles (VLP) encapsidating a cytokine genetic adjuvant. Plasmid DNA expressing interleukin-2 (pIL2) was encapsidated in VLP using the reassembly property of VLP from disassembled L1 capsomeres. pIL2 in reassembled VLP showed stability against DNase I, indicating encapsidation. After intramuscular immunization into mice, the highest vaginal and salivary HPV16 L1-specific IgA titers were observed in pIL2-encapsidated VLP, followed by VLP plus pIL2 in separate plasmid, and VLP alone. Similar to mucosal responses, serum IgG, IgG 1, and IgG 2a antibody titers were the highest in the group treated with pIL2-encapsidated VLP. Moreover, the adjuvanticity of pIL2 encapsidated in VLP was stronger in IgG 2a antibody relative to IgG 1 antibody. Our results indicate that the encapsidation of a genetic cytokine adjuvant pIL2 would be beneficial for more effective induction of mucosal and systemic immune responses to VLP vaccines.

Original languageEnglish
Pages (from-to)266-273
Number of pages8
JournalVirology
Volume328
Issue number2
DOIs
Publication statusPublished - 2004 Oct 25
Externally publishedYes

Fingerprint

Virion
Interleukin-2
Genes
Immunoglobulin G
Antibodies
Plasmids
Virus-Like Particle Vaccines
Cytokines
Mucosal Immunity
Human papillomavirus 16
Deoxyribonuclease I
Immunoglobulin A
Immunization
DNA
Serum

Keywords

  • Encapsidation
  • Genetic adjuvant
  • Human papillomavirus-like particles
  • Interleukin-2
  • Mucosal immune responses

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. / Oh, Yu Kyoung; Sohn, Taejong; Park, Jeong Sook; Kang, Min Jeong; Choi, Han Gon; Kim, Jung Ae; Kim, Won-Ki; Jae Ko, Jung; Kim, Chong Kook.

In: Virology, Vol. 328, No. 2, 25.10.2004, p. 266-273.

Research output: Contribution to journalArticle

Oh, Yu Kyoung ; Sohn, Taejong ; Park, Jeong Sook ; Kang, Min Jeong ; Choi, Han Gon ; Kim, Jung Ae ; Kim, Won-Ki ; Jae Ko, Jung ; Kim, Chong Kook. / Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. In: Virology. 2004 ; Vol. 328, No. 2. pp. 266-273.
@article{6845e4b5d3894951b5581ff46bf614b3,
title = "Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant",
abstract = "Here, we report the enhanced mucosal and systemic immunogenicity of human papillomavirus type (HPV) 16 L1 virus-like particles (VLP) encapsidating a cytokine genetic adjuvant. Plasmid DNA expressing interleukin-2 (pIL2) was encapsidated in VLP using the reassembly property of VLP from disassembled L1 capsomeres. pIL2 in reassembled VLP showed stability against DNase I, indicating encapsidation. After intramuscular immunization into mice, the highest vaginal and salivary HPV16 L1-specific IgA titers were observed in pIL2-encapsidated VLP, followed by VLP plus pIL2 in separate plasmid, and VLP alone. Similar to mucosal responses, serum IgG, IgG 1, and IgG 2a antibody titers were the highest in the group treated with pIL2-encapsidated VLP. Moreover, the adjuvanticity of pIL2 encapsidated in VLP was stronger in IgG 2a antibody relative to IgG 1 antibody. Our results indicate that the encapsidation of a genetic cytokine adjuvant pIL2 would be beneficial for more effective induction of mucosal and systemic immune responses to VLP vaccines.",
keywords = "Encapsidation, Genetic adjuvant, Human papillomavirus-like particles, Interleukin-2, Mucosal immune responses",
author = "Oh, {Yu Kyoung} and Taejong Sohn and Park, {Jeong Sook} and Kang, {Min Jeong} and Choi, {Han Gon} and Kim, {Jung Ae} and Won-Ki Kim and {Jae Ko}, Jung and Kim, {Chong Kook}",
year = "2004",
month = "10",
day = "25",
doi = "10.1016/j.virol.2004.06.047",
language = "English",
volume = "328",
pages = "266--273",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant

AU - Oh, Yu Kyoung

AU - Sohn, Taejong

AU - Park, Jeong Sook

AU - Kang, Min Jeong

AU - Choi, Han Gon

AU - Kim, Jung Ae

AU - Kim, Won-Ki

AU - Jae Ko, Jung

AU - Kim, Chong Kook

PY - 2004/10/25

Y1 - 2004/10/25

N2 - Here, we report the enhanced mucosal and systemic immunogenicity of human papillomavirus type (HPV) 16 L1 virus-like particles (VLP) encapsidating a cytokine genetic adjuvant. Plasmid DNA expressing interleukin-2 (pIL2) was encapsidated in VLP using the reassembly property of VLP from disassembled L1 capsomeres. pIL2 in reassembled VLP showed stability against DNase I, indicating encapsidation. After intramuscular immunization into mice, the highest vaginal and salivary HPV16 L1-specific IgA titers were observed in pIL2-encapsidated VLP, followed by VLP plus pIL2 in separate plasmid, and VLP alone. Similar to mucosal responses, serum IgG, IgG 1, and IgG 2a antibody titers were the highest in the group treated with pIL2-encapsidated VLP. Moreover, the adjuvanticity of pIL2 encapsidated in VLP was stronger in IgG 2a antibody relative to IgG 1 antibody. Our results indicate that the encapsidation of a genetic cytokine adjuvant pIL2 would be beneficial for more effective induction of mucosal and systemic immune responses to VLP vaccines.

AB - Here, we report the enhanced mucosal and systemic immunogenicity of human papillomavirus type (HPV) 16 L1 virus-like particles (VLP) encapsidating a cytokine genetic adjuvant. Plasmid DNA expressing interleukin-2 (pIL2) was encapsidated in VLP using the reassembly property of VLP from disassembled L1 capsomeres. pIL2 in reassembled VLP showed stability against DNase I, indicating encapsidation. After intramuscular immunization into mice, the highest vaginal and salivary HPV16 L1-specific IgA titers were observed in pIL2-encapsidated VLP, followed by VLP plus pIL2 in separate plasmid, and VLP alone. Similar to mucosal responses, serum IgG, IgG 1, and IgG 2a antibody titers were the highest in the group treated with pIL2-encapsidated VLP. Moreover, the adjuvanticity of pIL2 encapsidated in VLP was stronger in IgG 2a antibody relative to IgG 1 antibody. Our results indicate that the encapsidation of a genetic cytokine adjuvant pIL2 would be beneficial for more effective induction of mucosal and systemic immune responses to VLP vaccines.

KW - Encapsidation

KW - Genetic adjuvant

KW - Human papillomavirus-like particles

KW - Interleukin-2

KW - Mucosal immune responses

UR - http://www.scopus.com/inward/record.url?scp=5344235374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5344235374&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2004.06.047

DO - 10.1016/j.virol.2004.06.047

M3 - Article

C2 - 15464846

AN - SCOPUS:5344235374

VL - 328

SP - 266

EP - 273

JO - Virology

JF - Virology

SN - 0042-6822

IS - 2

ER -